biotech · Advanced Solid Tumor · Solid Tumor, Adult · IMMX
Immix Biopharma
Immix Biopharma is a biotech organization headquartered in Los Angeles, USA. It trades on NYSE under ticker IMMX. Primary therapeutic focus areas include Advanced Solid Tumor, Solid Tumor, Adult, Light Chain (AL) Amyloid
Los Angeles, USA HQ
2012 Founded
39 Employees
Public company Type
IMMX · NYSE Ticker
Company details
- Status
- Public
- HQ
- Los Angeles, USA
- Founded
- 2012
- Employees
- 39
- Programs
- 3
- Drugs
- 2
- Patents
- 2
IMX-110 combined with Tislelizumab
Phase 2 · small molecule · Advanced Solid Tumor
IMX-110 combined with Tislelizumab for Advanced Solid Tumor is a Phase 2 program (small_molecule) at Immix Biopharma with 1 ClinicalTrials.gov record(s).
Internal code IMX-110-002
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Immix Biopharma
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Advanced Solid Tumor
- Status
- active
- Trials
- 1